DK2764367T3 - Fremgangsmåde til diagnostisering af alzheimer s sygdom (ad) - Google Patents
Fremgangsmåde til diagnostisering af alzheimer s sygdom (ad) Download PDFInfo
- Publication number
- DK2764367T3 DK2764367T3 DK12761989.8T DK12761989T DK2764367T3 DK 2764367 T3 DK2764367 T3 DK 2764367T3 DK 12761989 T DK12761989 T DK 12761989T DK 2764367 T3 DK2764367 T3 DK 2764367T3
- Authority
- DK
- Denmark
- Prior art keywords
- aggregates
- sample
- antibodies
- specific
- patients
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 133
- 238000000034 method Methods 0.000 title claims description 89
- 239000000523 sample Substances 0.000 claims description 52
- 238000001514 detection method Methods 0.000 claims description 38
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 32
- 210000002966 serum Anatomy 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 206010012289 Dementia Diseases 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 6
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000011088 calibration curve Methods 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 2
- 230000035876 healing Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 230000009257 reactivity Effects 0.000 description 45
- 238000003556 assay Methods 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 238000013211 curve analysis Methods 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 208000027061 mild cognitive impairment Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004201 immune sera Anatomy 0.000 description 4
- 229940042743 immune sera Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940043517 specific immunoglobulins Drugs 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000012774 diagnostic algorithm Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000006951 hyperphosphorylation Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012083 mass cytometry Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101800001718 Amyloid-beta protein Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000007351 Aβ plaque formation Effects 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000001593 atomic mass spectrometry Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108010027090 biotin-streptavidin complex Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 description 1
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011898 label-free detection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003949 synaptic integrity Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Sampling And Sample Adjustment (AREA)
Claims (14)
1. Fremgangsmåde til diagnostisering af Alzheimer's sygdom (AD) hvor de Αβ-specifikke antistoffer i en biologisk prøve fra en person der er mistænkt for at have AD er påvist omfattende følgende trin: - bringe prøven i kontakt med Αβ-aggregater og tillade de Αβ-specifikke antistoffer at binde til Αβ-aggregaterne, og - påvise de Αβ-specifikke antistoffer bundet til Αβ-aggregaterne ved en enkeltpartikel påvisningsteknik, fortrinsvis ved fluorescens aktiveret cellesortering (FACS); og hvor mængden af påviste Αβ-specifikke antistoffer sammenlignes med mængden i en prøve af kendt AD-status.
2. Fremgangsmåde ifølge krav 1, kendetegnet ved at de Αβ-specifikke antistoffer er humane antistoffer, fortrinsvis humane IgG- eller IgM-antistoffer, især humane IgG-antistoffer.
3. Fremgangsmåde ifølge krav 1 eller 2, kendetegnet ved at de Αβ-specifikke antistoffer er autoantistoffer.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved at Αβ-aggregaterne har en størrelse på 50 nm til 15 pm, fortrinsvis fra 100 nm til 10 pm, især fra 200 nm til 5 pm.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved at Αβ-aggregaterne er fremstillet ved inkubering af Αβ-Ι-42-peptider, Αβ-1-43-peptider, Αβ-3-42, eller Αβ-ρ(Ε)3-42-ρερΜεΓ ved pH på 2 til 9 i mindst 20 min, fortrinsvis mindst 1 time, især mindst 4 timer.
6. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved at Αβ-aggregaterne er til stede for at bringe prøven i kontakt med Αβ-aggregaterne i en mængde på 0,001 til 1 pM, fortrinsvis 0,01 til 0,1 pM.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, kendetegnet ved at den biologiske prøve er humant blod eller en prøve afledt fra humant blod, fortrinsvis humant serum eller humant plasma; human cerebrospinalvæske eller human lymfe.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 7, kendetegnet ved at Αβ-aggregaterne bringes i kontakt med prøven i mindst 10 min, fortrinsvis fra 10 min til 24 timer, især fra 20 min til 2 timer.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 8, hvor prøven af kendt AD-status er en prøve fra en patient med AD eller en prøve fra en rask person.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 9, hvor prøven af kendt AD-status er en AD-status kalibreringskurve, specielt en Mini-Mental State examination (MMSE)-kurve.
11. Anvendelse af en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10 til overvågningen af AD-patienter, især AD-patienter der er behandlet med medikamenter til helbredelse eller lindring af AD.
12. Anvendelse af en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 10 til evaluering af risikoen for at udvikle AD eller for at påvise tidligt stadie AD.
13. Anvendelse af en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 12 til diagnosen af Parkinson's demens (PDD), demens med Lewy Bodies (DLB), Cerebral Amyloid Angiopati (CAA), Inclusion body myositis (IBM), eller kronisk hovedtraume.
14. Anvendelse af et kit omfattende - Αβ-aggregater, og - en prøvebeholder til udførelse af fremgangsmåden ifølge et hvilket som helst af kravene 1 til 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11183842.1A EP2579042B1 (en) | 2011-10-04 | 2011-10-04 | Method for detecting Aß-specific antibodies in a biological sample |
| PCT/EP2012/068493 WO2013050248A1 (en) | 2011-10-04 | 2012-09-20 | Method for diagnosing alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2764367T3 true DK2764367T3 (da) | 2018-10-29 |
Family
ID=46888451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11183842.1T DK2579042T3 (da) | 2011-10-04 | 2011-10-04 | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
| DK12761989.8T DK2764367T3 (da) | 2011-10-04 | 2012-09-20 | Fremgangsmåde til diagnostisering af alzheimer s sygdom (ad) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11183842.1T DK2579042T3 (da) | 2011-10-04 | 2011-10-04 | Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20140234877A1 (da) |
| EP (3) | EP2579042B1 (da) |
| JP (2) | JP6162127B2 (da) |
| KR (2) | KR20140073568A (da) |
| CN (2) | CN103842825B (da) |
| AR (1) | AR088108A1 (da) |
| AU (2) | AU2012320766B2 (da) |
| BR (2) | BR112014008089A2 (da) |
| CA (2) | CA2850840A1 (da) |
| CY (1) | CY1115624T1 (da) |
| DK (2) | DK2579042T3 (da) |
| ES (2) | ES2496341T3 (da) |
| HR (1) | HRP20140937T1 (da) |
| IL (2) | IL231057A0 (da) |
| MX (2) | MX2014003983A (da) |
| PL (2) | PL2579042T3 (da) |
| PT (1) | PT2579042E (da) |
| RS (1) | RS53496B1 (da) |
| RU (2) | RU2014117671A (da) |
| SG (2) | SG11201400229XA (da) |
| SI (1) | SI2579042T1 (da) |
| SM (1) | SMT201400145B (da) |
| WO (2) | WO2013050249A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2787347A1 (en) * | 2013-04-03 | 2014-10-08 | Affiris AG | Method for detecting Aß-specific antibodies in a biological sample |
| EP2787349A1 (en) | 2013-04-03 | 2014-10-08 | Affiris AG | Method for detecting proteinopathy-specific antibodies in a biological sample |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| KR101658620B1 (ko) * | 2014-12-02 | 2016-09-23 | 주식회사 피플바이오 | 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법 |
| KR20170108203A (ko) * | 2016-03-16 | 2017-09-27 | 주식회사 피플바이오 | 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법 |
| KR101871895B1 (ko) * | 2016-04-20 | 2018-06-28 | 한국과학기술연구원 | 응집 단백질의 고감도 광 산화 증폭 면역 분석을 통한 체액기반의 퇴행성 신경질환 진단 방법 |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| KR101989383B1 (ko) * | 2017-04-04 | 2019-06-14 | 조선대학교산학협력단 | 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브 |
| KR102108171B1 (ko) * | 2018-08-27 | 2020-05-08 | 광주과학기술원 | 알츠하이머성 치매 진단용 펩타이드 바이오마커 |
| WO2020045962A1 (ko) * | 2018-08-27 | 2020-03-05 | 광주과학기술원 | 알츠하이머성 치매 진단용 펩타이드 바이오마커 |
| CN113075398A (zh) * | 2021-03-23 | 2021-07-06 | 中国医学科学院输血研究所 | 一种血浆中特异性IgG抗体的定量测定方法 |
| CN113063949B (zh) * | 2021-03-23 | 2024-11-15 | 中国医学科学院输血研究所 | 一种血浆中特异性IgM抗体的定量测定方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262332A (en) | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
| AU8083094A (en) * | 1994-10-19 | 1996-05-15 | General Hospital Corporation, The | A diagnostic assay for alzheimer's disease: assessment of abeta abnormalities |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AT413945B (de) | 2003-01-14 | 2006-07-15 | Mattner Frank Dr | Impfstoff für die alzheimer-krankheit |
| KR100595494B1 (ko) * | 2003-02-24 | 2006-07-03 | (주) 디지탈바이오텍 | 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트 |
| AT413336B (de) | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| AT413946B (de) | 2004-07-13 | 2006-07-15 | Mattner Frank Dr | Impfstoff gegen die alzheimer-krankheit |
| DE102005006217B4 (de) * | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| TW200700432A (en) * | 2005-03-05 | 2007-01-01 | Abbott Gmbh & Co Kg | Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| BRPI0613358A8 (pt) * | 2005-07-08 | 2017-12-26 | Dsm Ip Assets Bv | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência |
| EP1959996A2 (en) * | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| TW200844110A (en) * | 2007-01-11 | 2008-11-16 | Univ Marburg Philipps | Diagnosis and treatment of alzheimer's disease and other neurodementing diseases |
| US7771957B2 (en) * | 2007-10-19 | 2010-08-10 | The Regents Of The University Of California | Method for diagnosing alzheimer's disease |
| WO2009051599A1 (en) * | 2007-10-19 | 2009-04-23 | The Regents Of The University Of California | Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| CN102123726A (zh) | 2008-06-12 | 2011-07-13 | 阿费里斯股份公司 | 用于治疗与帕金森氏病有关的症状的化合物 |
| AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| WO2010099199A1 (en) * | 2009-02-24 | 2010-09-02 | Gibbons Winton G | Detection of complexes of tau and amyloid |
| WO2010128139A1 (en) | 2009-05-08 | 2010-11-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| US20130084245A1 (en) | 2010-02-25 | 2013-04-04 | Wyeth Llc | Pet monitoring of a-beta-directed immunotherapy |
-
2011
- 2011-10-04 PT PT111838421T patent/PT2579042E/pt unknown
- 2011-10-04 DK DK11183842.1T patent/DK2579042T3/da active
- 2011-10-04 SI SI201130248T patent/SI2579042T1/sl unknown
- 2011-10-04 ES ES11183842.1T patent/ES2496341T3/es active Active
- 2011-10-04 PL PL11183842T patent/PL2579042T3/pl unknown
- 2011-10-04 RS RSP20140412 patent/RS53496B1/sr unknown
- 2011-10-04 EP EP11183842.1A patent/EP2579042B1/en not_active Not-in-force
-
2012
- 2012-09-20 AU AU2012320766A patent/AU2012320766B2/en not_active Ceased
- 2012-09-20 PL PL12761989T patent/PL2764367T3/pl unknown
- 2012-09-20 RU RU2014117671/15A patent/RU2014117671A/ru not_active Application Discontinuation
- 2012-09-20 DK DK12761989.8T patent/DK2764367T3/da active
- 2012-09-20 MX MX2014003983A patent/MX2014003983A/es not_active Application Discontinuation
- 2012-09-20 SG SG11201400229XA patent/SG11201400229XA/en unknown
- 2012-09-20 EP EP12762576.2A patent/EP2764368A1/en not_active Withdrawn
- 2012-09-20 US US14/348,788 patent/US20140234877A1/en not_active Abandoned
- 2012-09-20 WO PCT/EP2012/068494 patent/WO2013050249A1/en not_active Ceased
- 2012-09-20 AU AU2012320767A patent/AU2012320767A1/en not_active Abandoned
- 2012-09-20 SG SG11201400223SA patent/SG11201400223SA/en unknown
- 2012-09-20 RU RU2014117677/15A patent/RU2014117677A/ru not_active Application Discontinuation
- 2012-09-20 MX MX2014003984A patent/MX2014003984A/es not_active Application Discontinuation
- 2012-09-20 ES ES12761989.8T patent/ES2692185T3/es active Active
- 2012-09-20 EP EP12761989.8A patent/EP2764367B1/en not_active Not-in-force
- 2012-09-20 CA CA2850840A patent/CA2850840A1/en not_active Abandoned
- 2012-09-20 JP JP2014533825A patent/JP6162127B2/ja not_active Expired - Fee Related
- 2012-09-20 BR BR112014008089A patent/BR112014008089A2/pt not_active IP Right Cessation
- 2012-09-20 US US14/346,910 patent/US9625459B2/en not_active Expired - Fee Related
- 2012-09-20 JP JP2014533826A patent/JP2014529088A/ja not_active Withdrawn
- 2012-09-20 KR KR1020147012158A patent/KR20140073568A/ko not_active Withdrawn
- 2012-09-20 BR BR112014008088A patent/BR112014008088A2/pt not_active IP Right Cessation
- 2012-09-20 CN CN201280049131.8A patent/CN103842825B/zh not_active Expired - Fee Related
- 2012-09-20 CA CA2850843A patent/CA2850843A1/en not_active Abandoned
- 2012-09-20 CN CN201280049115.9A patent/CN103842824A/zh active Pending
- 2012-09-20 WO PCT/EP2012/068493 patent/WO2013050248A1/en not_active Ceased
- 2012-09-20 KR KR1020147012156A patent/KR20140069346A/ko not_active Withdrawn
- 2012-10-03 AR ARP120103680A patent/AR088108A1/es unknown
-
2014
- 2014-02-20 IL IL231057A patent/IL231057A0/en unknown
- 2014-03-20 IL IL231620A patent/IL231620A0/en unknown
- 2014-09-30 HR HRP20140937AT patent/HRP20140937T1/hr unknown
- 2014-10-03 CY CY20141100799T patent/CY1115624T1/el unknown
- 2014-10-09 SM SM201400145T patent/SMT201400145B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2764367T3 (da) | Fremgangsmåde til diagnostisering af alzheimer s sygdom (ad) | |
| EP3415909B1 (en) | Diagnosis of a neuroautoimmune disease | |
| WO2014161875A1 (en) | METHOD FOR DETECTING Aβ-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE | |
| EP3242134A1 (en) | Assay for the diagnosis of a neurological disease | |
| WO2014161890A1 (en) | Method for detecting proteinopathy-specific antibodies in a biological sample | |
| HK1178601B (en) | METHOD FOR DETECTING Aß-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE | |
| DK2981824T3 (da) | FREMGANGSMÅDE TIL PÅVISNING AF aSYN-SPECIFIKKE ANTISTOFFER I EN BIOLOGISK PRØVE | |
| HK1194468A (en) | METHOD FOR DETECTING Aβ-SPECIFIC ANTIBODIES IN A BIOLOGICAL SAMPLE | |
| TW201316000A (zh) | 一種偵測生物樣本中Ａβ抗體的方法 | |
| Funke et al. | Detection and Quantitation of Amyloid-β Aggregates in Body Fluids may be Suitable for Early Diagnosis of Alzheimer's Disease |